Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00762255 · ClinicalTrials.gov registry record · Phase 1
A Phase I Trial of Vorinostat in Combination With Bevacizumab & Irinotecan in Recurrent Glioblastoma
A Phase 1 study of Glioblastoma, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
- 1
- Study location
NCT00762255 is a Phase 1 study of Glioblastoma that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 19 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00762255, a Phase 1 study of Glioblastoma, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the this study is to see if an investigations cancer treatment called vorinostat can be combined with the irinotecan/bevacizumab regimen safely.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Irinotecan
- DRUG Vorinostat
Study Locations (1)
Florida
- H. Lee Moffitt Cancer Center & Research Institute, Inc. - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2008-09 |
| Est. Completion | 2013-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00762255
The ClinicalTrials.gov registry entry for NCT00762255 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (83% lower). The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glioblastoma appearing as the primary indexed condition, and to 3 interventions - of which Bevacizumab is the first listed.
NCT00762255 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT00762255 about?
NCT00762255 is a clinical study titled "A Phase I Trial of Vorinostat in Combination With Bevacizumab & Irinotecan in Recurrent Glioblastoma". The purpose of the this study is to see if an investigations cancer treatment called vorinostat can be combined with the irinotecan/bevacizumab regimen safely.
What is the current status of trial NCT00762255?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2008-09. Estimated completion is 2013-07.
What conditions does trial NCT00762255 study?
This clinical trial studies the following conditions: Glioblastoma.
What interventions are being tested in trial NCT00762255?
The interventions under investigation include: Bevacizumab (DRUG), Irinotecan (DRUG), Vorinostat (DRUG).
Who is sponsoring clinical trial NCT00762255?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00762255 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
RECRUITING · Phase 1
-
CARv3-TEAM-E T Cells in Glioblastoma
RECRUITING · Phase 1
-
CUE-102 in Recurrent Glioblastoma
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.